Orthocell’s PearlBone Option Clears a Major US Regulatory Hurdle

PearlBone Clears US Regulatory Barrier

Orthocell Limited (ASX:OCC) now has a more valuable option on a second regenerative medicine growth avenue after strategic partner Marine Biomedical received US Food and Drug Administration 510(k) clearance for PearlBone, a bone graft substitute made from sustainably sourced pearl shell.

The clearance enables PearlBone to be marketed in the United States for its cleared indications, although the announcement does not specify what those indications are. It removes a key regulatory hurdle in one of the world’s largest medical device markets, moving the product from development and regulatory preparation towards commercial launch.

Orthocell Holds Equity and Distribution Rights

Orthocell finalised a A$1.05 million investment in Marine Biomedical in January 2026, giving it a 12% equity interest. The agreement also secured a first right of refusal over global distribution rights for PearlBone and future bone repair and regeneration products.

That right is not the same as a distribution agreement. Orthocell said any role in commercialising PearlBone would depend on exercising its contractual rights and agreeing definitive commercial arrangements. Still, the clearance gives the company a clearer basis to assess whether its US surgeon relationships, distributor network and commercial infrastructure can be applied to the bone product.

Marine-Derived Technology Targets Bone Repair

PearlBone uses nacre, the biomineralised structure of pearl shell, to support bone repair and regeneration. Marine Biomedical sources the material from Western Australia’s Kimberley region and manufactures the product at a purpose-built facility in Broome, with potential applications across orthopaedic, trauma and reconstructive surgery.

For Orthocell, the attraction is portfolio breadth. The company’s established products focus on nerve and tendon repair, while PearlBone offers exposure to bone regeneration without Orthocell having to develop the underlying technology itself. The announcement describes the opportunity as complementary, but provides no estimate of the product’s future revenue contribution or the value of any distribution economics.

Commercial Preparation Moves to the Fore

Marine Biomedical is now working through manufacturing readiness, market development and discussions with potential commercial and clinical partners ahead of the planned US introduction. Those steps will determine how quickly regulatory clearance can translate into supply, surgeon adoption and sales.

The next evidence will therefore be practical rather than regulatory: a launch timetable, a definitive distribution arrangement, manufacturing scale-up and initial commercial traction. Until those details emerge, PearlBone is best viewed as a cleared and strategically important opportunity for Orthocell, rather than a disclosed source of near-term revenue.